ONgoing Telmisartan Alone or in combination with Ramipril Global Endpoint Trial

Boehringer Ingelheim (Canada) Ltd0 个研究点目标入组 31,546 人开始时间: 2002年12月18日最近更新: 2016年10月17日

适应症

试验速览

暂无简介。

•1. Adults greater than or equal to 55 years
•2. With a history of symptomatic coronary artery disease, cerebrovascular disease, peripheral vascular disease, or diabetes mellitus
•3. Coronary Artery Disease: previous MI (greater than 2 days prior to informed consent), or stable or previous unstable angina (greater than 30 days prior to informed consent) with documented multivessel coronary artery disease or a positive stress test, or multivessel Percutaneous Transluminal Coronary Angioplasty (PTCA) (greater than 30 days prior to informed consent), or previous multivessel Coronary Artery Bypass Graft (CABG) without angina (if surgery performed greater than 4 years prior to informed consent) or with recurrent angina after surgery
•4. No definite and specific indication or contraindication for any of the study treatments
•5. Written informed consent
•Other High Risk:
•6. Peripheral Arterial Disease: previous limb bypass surgery or angioplasty or amputation, intermittent claudication on history with ankle/arm Blood Pressure (BP) ratio less than 0.8 on at least one side, or significant stenosis by angiography or non-invasive testing
•7. Previous stroke
•8. Transient Ischaemic Attach (TIA) greater than 7 days and less than 1 year prior to informed consent
•9. Diabetes Mellitus (types I or II): with evidence of end-organ damage (retinopathy, Left Ventricular Hypertrophy [LVH], micro- or macro-albuminuria), or any evidence of previous cardiac or vascular disease

发起方